Perspective Therapeutics Inc (AMEX:CATX)’s traded shares stood at 2.22 million during the last session, with the company’s beta value hitting 1.23. At the close of trading, the stock’s price was $1.90, to imply an increase of 11.11% or $0.19 in intraday trading. The CATX share’s 52-week high remains $19.05, putting it -902.63% down since that peak but still an impressive 14.74% since price per share fell to its 52-week low of $1.62. The company has a valuation of $140.70M, with an average of 1.13 million shares in intraday trading volume over the past 10 days and average of 784.71K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Perspective Therapeutics Inc (CATX), translating to a mean rating of 1.14. Of 4 analyst(s) looking at the stock, 0 analyst(s) give CATX a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 4 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.27.
Perspective Therapeutics Inc (AMEX:CATX) trade information
After registering a 11.11% upside in the last session, Perspective Therapeutics Inc (CATX) has traded red over the past five days. The 5-day price performance for the stock is -7.32%, and -24.00% over 30 days. With these gigs, the year-to-date price performance is -40.44%. Short interest in Perspective Therapeutics Inc (AMEX:CATX) saw shorts transact 5.94 million shares and set a 10.36 days time to cover.
The extremes give us $20 and $22 for target low and target high price respectively. As such, CATX has been trading -1057.89% off suggested target high and -952.63% from its likely low.
Perspective Therapeutics Inc (CATX) estimates and forecasts
The rating firms project that company’s revenue will shrink -54.06% compared to the previous financial year.
Revenue forecast for the current quarter as set by 10 analysts is 143.93k. Meanwhile, for the current quarter, a total of 10 analyst(s) estimate revenue growth to 123.17k.Earnings reports from the last fiscal year show that sales brought in 325k and 526k respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -55.71% before dropping -76.58% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -9.86% for the past 5-year period. While 2025 is set for a -3.85% return in earnings, projections for the next 5 years are at -8.41% annually.
CATX Dividends
Perspective Therapeutics Inc has its next earnings report out on 2025-Mar-25. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Perspective Therapeutics Inc (AMEX:CATX)’s Major holders
Perspective Therapeutics Inc insiders hold 18.71% of total outstanding shares, with institutional holders owning 64.38% of the shares at 79.20% float percentage. In total, 64.38% institutions holds shares in the company.
We also have VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund as the top two Mutual Funds with the largest holdings of the Perspective Therapeutics Inc (CATX) shares. Going by data provided on Dec 31, 2024 , VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund holds roughly 1.69 shares. This is just over 2.29% of the total shares, with a market valuation of $3.22 million. Data from the same date shows that the other fund manager holds a little less at 1.64, or 2.22% of the shares, all valued at about 3.12 million.
